Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Comparative Observational Study to Evaluate the Safety and Effectiveness of Xromi (Hydroxycarbamide Oral Solution 100mg/ml) for the Prevention of Vaso-occlusive Complications of Sickle Cell Disease in Children Under 2 Years of Age.

NCT06923111 is registered in ClinicalTrials.gov with Nova Laboratories Limited as lead sponsor.

NCT NCT06923111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06923111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Comparative Observational Study to Evaluate the Safety and Effectiveness of Xromi (Hydroxycarbamide Oral Solution 100mg/ml) for the Prevention of Vaso-occlusive Complications of Sickle Cell Disease in Children Under 2 Years of Age.
Lead sponsor
Nova Laboratories Limited
Phase
Observational
Overall status
Recruiting
Start date
June 9, 2025
Completion date
June 30, 2029
Enrollment
180 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease